2023
Arketamine as adjunctive therapy for treatment-resistant depression: A placebo-controlled pilot study
Leal G, Souza-Marques B, Mello R, Bandeira I, Caliman-Fontes A, Carneiro B, Faria-Guimarães D, Guerreiro-Costa L, Jesus-Nunes A, Silva S, Lins-Silva D, Fontes M, Alves-Pereira R, Cordeiro V, Rugieri-Pacheco S, Santos-Lima C, Correia-Melo F, Vieira F, Sanacora G, Lacerda A, Quarantini L. Arketamine as adjunctive therapy for treatment-resistant depression: A placebo-controlled pilot study. Journal Of Affective Disorders 2023, 330: 7-15. PMID: 36871913, DOI: 10.1016/j.jad.2023.02.151.Peer-Reviewed Original ResearchConceptsTreatment-resistant depressionAntidepressant effectsPlacebo-controlled pilot studyPilot studyMain efficacy analysisAdjunctive therapyAdverse eventsOne-week intervalEfficacy analysisPreclinical dataFlexible dosesClinical trialsPilot trialHuman trialsSide effectsRacemic ketaminePlaceboFirst weekKetamineTrialsTreatment effectsSignificant differencesDepressionEffects modelParallel design
2022
Duloxetine for prevention and treatment of chemotherapy-induced peripheral neuropathy (CIPN): systematic review and meta-analysis
Chow R, Novosel M, So OW, Bellampalli S, Xiang J, Boldt G, Winquist E, Lock M, Lustberg M, Prsic E. Duloxetine for prevention and treatment of chemotherapy-induced peripheral neuropathy (CIPN): systematic review and meta-analysis. BMJ Supportive & Palliative Care 2022, 13: 27-34. PMID: 36194493, DOI: 10.1136/spcare-2022-003815.Peer-Reviewed Original ResearchConceptsChemotherapy-induced peripheral neuropathyTreatment of CIPNDuloxetine usePeripheral neuropathyRisk ratioPrevention of CIPNSystematic reviewUse of duloxetineSummary risk ratiosClinical practice recommendationsHigh-quality trialsDerSimonian-Laird modelComprehensive systematic reviewCochrane CENTRALSafety profileDatabase inceptionHuman trialsDuloxetinePractice recommendationsLimited evidencePreventionTrialsNeuropathyTreatmentReview
2021
A systematic review of immunomodulatory strategies used in skin-containing preclinical vascularized composite allotransplant models
Kauke M, Safi AF, Panayi AC, Palmer WJ, Haug V, Kollar B, Nelms L, Tchiloemba B, Pomahac B. A systematic review of immunomodulatory strategies used in skin-containing preclinical vascularized composite allotransplant models. Journal Of Plastic Reconstructive & Aesthetic Surgery 2021, 75: 586-604. PMID: 34895853, DOI: 10.1016/j.bjps.2021.11.003.Peer-Reviewed Original ResearchConceptsSystematic reviewImmunomodulatory strategiesPreclinical researchAvailable immunosuppressive regimensCurrent standard regimenSystemic side effectsDrug-based approachesMeta-Analyses (PRISMA) guidelinesVCA modelPreferred Reporting ItemsHind limb modelNovel immunomodulatoryRejection episodesAcute rejectionImmunosuppressive regimensStandard regimenAllograft acceptanceAlloimmune responseSuppression therapyImmunomodulation strategiesLimb transplantsPreclinical modelsRat modelHuman trialsTherapeutic approachesContinuous Ketone Monitoring Consensus Report 2021
Nguyen KT, Xu NY, Zhang JY, Shang T, Basu A, Bergenstal RM, Castorino K, Chen KY, Kerr D, Koliwad SK, Laffel LM, Mathioudakis N, Midyett LK, Miller JD, Nichols JH, Pasquel FJ, Prahalad P, Prausnitz MR, Seley JJ, Sherr JL, Spanakis EK, Umpierrez GE, Wallia A, Klonoff DC. Continuous Ketone Monitoring Consensus Report 2021. Journal Of Diabetes Science And Technology 2021, 16: 689-715. PMID: 34605694, PMCID: PMC9294575, DOI: 10.1177/19322968211042656.Peer-Reviewed Original ResearchConceptsDiabetic ketoacidosisMedical literaturePrevention of DKAAdvanced practice nursingAdult endocrinologyDiabetes Technology SocietyClinical trialsInsulin delivery systemsConsensus panelHuman trialsPractice nursingPediatric endocrinologyKetone monitoringPrivate practiceDiabetes technologyClinical chemistryKetone productionTrialsEndocrinologyDelivery systemReportConclusionKetoacidosisKetonuriaKetonemiaWheat oral immunotherapy
Leeds S, Liu EG, Nowak-Wegrzyn A. Wheat oral immunotherapy. Current Opinion In Allergy And Clinical Immunology 2021, 21: 269-277. PMID: 33840798, DOI: 10.1097/aci.0000000000000743.Peer-Reviewed Original ResearchConceptsWheat oral immunotherapyOral immunotherapyMaintenance dosesSevere reactionsFood allergy epidemiologyLow maintenance dosesNonrandomized clinical trialRisk of reactionSustained unresponsivenessSuccessful desensitizationAdjunct therapeuticsFood allergyTrial protocolClinical trialsAllergic reactionsAllergy epidemiologyHuman trialsSafety outcomesHead comparisonAugmenting factorSmall sample sizeTrialsFood modificationImmunotherapyDosesMolecular subtyping of Alzheimer’s disease using RNA sequencing data reveals novel mechanisms and targets
Neff R, Wang M, Vatansever S, Guo L, Ming C, Wang Q, Wang E, Horgusluoglu-Moloch E, Song W, Li A, Castranio E, Julia T, Ho L, Goate A, Fossati V, Noggle S, Gandy S, Ehrlich M, Katsel P, Schadt E, Cai D, Brennand K, Haroutunian V, Zhang B. Molecular subtyping of Alzheimer’s disease using RNA sequencing data reveals novel mechanisms and targets. Science Advances 2021, 7: eabb5398. PMID: 33523961, PMCID: PMC7787497, DOI: 10.1126/sciadv.abb5398.Peer-Reviewed Original ResearchConceptsAlzheimer's diseaseMouse modelAD mouse modelDiverse pathophysiologic mechanismsTau-mediated neurodegenerationMajor molecular subtypesSpecific mouse modelsPathophysiologic mechanismsHuman trialsMolecular subtypesImmune activityHeterogeneous diseaseAD cohortAD subtypesBrain regionsSynaptic signalingMolecular subtypingSubtype heterogeneityDiseaseCommon formPrecision medicineMultiscale network analysisDevastating diseaseMolecular heterogeneitySubtypes
2020
Stem Cell Delivery Techniques for Stroke and Peripheral Artery Disease
Lee S, Fereydooni A, Dardik A. Stem Cell Delivery Techniques for Stroke and Peripheral Artery Disease. 2020, 69-103. DOI: 10.1007/978-3-030-56954-9_3.ChaptersPeripheral artery diseaseArtery diseaseImpact of patientStem cellsVascular diseaseTherapeutic effectHuman trialsOptimal doseTarget organsPharmaceutic agentsCell therapyDiseaseCell delivery techniquesStrokeCell factorPatientsTherapyDelivery techniquesDiverse populationsDelivery methodsCellsDelivery optionsDoseTrialsLocal immunosuppression in vascularized composite allotransplantation (VCA): A systematic review
Safi AF, Kauke M, Nelms L, Palmer WJ, Tchiloemba B, Kollar B, Haug V, Pomahač B. Local immunosuppression in vascularized composite allotransplantation (VCA): A systematic review. Journal Of Plastic Reconstructive & Aesthetic Surgery 2020, 74: 327-335. PMID: 33229219, DOI: 10.1016/j.bjps.2020.10.003.Peer-Reviewed Original ResearchConceptsLocal immunosuppressionSystematic reviewAllograft survivalComposite allotransplantationAllograft survival dataCell-based therapy strategiesImproved allograft survivalMain immunosuppressive agentMeta-Analyses (PRISMA) guidelinesPreclinical animal studiesPreferred Reporting ItemsMalignant side effectsImmunosuppressive agentsPreclinical dataSignificant prolongationRat modelHuman trialsExclusion criteriaImmunosuppressionSide effectsAnimal studiesReporting ItemsPubMed databaseSystemic toxicityTherapy strategiesUtility of spontaneous animal models of Alzheimer’s disease in preclinical efficacy studies
Zeiss CJ. Utility of spontaneous animal models of Alzheimer’s disease in preclinical efficacy studies. Cell And Tissue Research 2020, 380: 273-286. PMID: 32337614, DOI: 10.1007/s00441-020-03198-6.Peer-Reviewed Original ResearchConceptsHuman Alzheimer's diseaseSpontaneous animal modelAlzheimer's diseaseAnimal modelsBiomarker progressionProgression of neuropathologyLate-onset Alzheimer's diseasePreclinical efficacy studiesHuman clinical trialsOnset Alzheimer's diseaseUsable outcome measuresAD-associated mutationsFamilial Alzheimer's diseaseNon-human primatesAmyloid neuropathologyInterventional studyClinical trialsSpontaneous modelHuman trialsOutcome measuresTherapeutic successPotential therapyNew therapiesRodent studiesEfficacy studies
2019
Use of immunomodulators to treat endometriosis
Kotlyar A, Taylor H, D'Hooghe T. Use of immunomodulators to treat endometriosis. Best Practice & Research Clinical Obstetrics & Gynaecology 2019, 60: 56-65. PMID: 31515196, DOI: 10.1016/j.bpobgyn.2019.06.006.Peer-Reviewed Original ResearchConceptsDisease-modifying antirheumatic drugsEndometriosis-associated painPro-inflammatory stateTreatment of endometriosisUse of immunomodulatorsImmune cell populationsLimited human trialsImmunomodulating therapiesAntirheumatic drugsSymptom controlImmune dysfunctionChronic diseasesHuman trialsMTOR inhibitorsAnimal modelsAnimal studiesHuman studiesEndometriosisAberrant cytokineElevated levelsCell populationsCytokinesDiseaseLittle benefitTreatment
2018
Does Dexmedetomidine Ameliorate Postoperative Cognitive Dysfunction? A Brief Review of the Recent Literature
Carr ZJ, Cios TJ, Potter KF, Swick JT. Does Dexmedetomidine Ameliorate Postoperative Cognitive Dysfunction? A Brief Review of the Recent Literature. Current Neurology And Neuroscience Reports 2018, 18: 64. PMID: 30083844, DOI: 10.1007/s11910-018-0873-z.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsUse of dexmedetomidinePostoperative deliriumCognitive dysfunctionAcute postoperative deliriumPostoperative cognitive dysfunctionAlpha-2 agonistsIncidence of POCDAnti-inflammatory propertiesHigh patient mortalityHospital lengthElderly patientsHeart failurePostsurgical patientsPatient mortalityImmunomodulatory effectsVascular diseaseBrain injuryFavorable outcomeClinical studiesDexmedetomidineHigh prevalenceHuman trialsClinical investigationRecent FindingsThereAnimal models
2017
Integrins, Immunology
de Moll E, Dong J, Oliva M, Saenger Y. Integrins, Immunology. 2017, 285-294. DOI: 10.1007/978-1-4419-0717-2_131.Peer-Reviewed Original ResearchSuccessful human trialsAnti-integrin antibodiesIntegrin blockadeClinical trialsHuman trialsRole of integrinsPrincipal receptorTumor growthTumor proliferationTumor cellsMetastasisIntegrin expressionCell functionExtracellular matrix proteinsMultiple mechanismsTrialsAngiogenesisIntegrinsMatrix proteinsProliferationCell signalingMajor roleBlockadeEpigenetics and Signaling Pathways in Glaucoma
Gauthier AC, Liu J. Epigenetics and Signaling Pathways in Glaucoma. BioMed Research International 2017, 2017: 5712341. PMID: 28210622, PMCID: PMC5292191, DOI: 10.1155/2017/5712341.Peer-Reviewed Original ResearchConceptsPotential new therapeutic targetGeneration of fibrosisNovel therapeutic agentsNew therapeutic targetsAqueous humor drainageProapoptotic gene expressionRetinal neuronsIrreversible blindnessCommon causeHuman trialsTherapeutic targetAnimal modelsTrabecular meshworkTherapeutic agentsNeurodegenerative diseasesProsurvival factorBcl-2Rho-kinaseGlaucomaSignaling pathwaysPathway membersMAP kinaseGene expressionPathwayPreliminary success
2016
Integrins, Immunology
de Moll E, Dong J, Oliva M, Saenger Y. Integrins, Immunology. 2016, 1-10. DOI: 10.1007/978-1-4614-6613-0_131-2.Peer-Reviewed Original ResearchSuccessful human trialsAnti-integrin antibodiesIntegrin blockadeClinical trialsHuman trialsRole of integrinsPrincipal receptorTumor growthTumor proliferationTumor cellsMetastasisIntegrin expressionCell functionExtracellular matrix proteinsMultiple mechanismsTrialsAngiogenesisIntegrinsMatrix proteinsProliferationCell signalingMajor roleBlockadePicosecond lasers for tattoo removal: a systematic review
Reiter O, Atzmony L, Akerman L, Levi A, Kershenovich R, Lapidoth M, Mimouni D. Picosecond lasers for tattoo removal: a systematic review. Lasers In Medical Science 2016, 31: 1397-1405. PMID: 27311768, DOI: 10.1007/s10103-016-2001-0.Peer-Reviewed Original ResearchConceptsSide effectsCochrane Central Register of Controlled TrialsCentral Register of Controlled TrialsNon-comparative studyRegister of Controlled TrialsReported side effectsCochrane Central RegisterClearance of pigmentTattoo pigmentTattoo removalTransient erythemaLaser sessionsPrimary outcomeSecondary outcomesHuman trialsAnimal modelsRelevant trialsHigh riskInk tattooingControlled Trials
2015
Phase I, first-in-human trial of LV305 in patients with advanced or metastatic cancer expressing NY-ESO-1.
Somaiah N, Block M, Kim J, Shapiro G, Hwu P, Eder J, Jones R, Gnjatic S, Lu H, Hsu F, Pollack S. Phase I, first-in-human trial of LV305 in patients with advanced or metastatic cancer expressing NY-ESO-1. Journal Of Clinical Oncology 2015, 33: 3021-3021. DOI: 10.1200/jco.2015.33.15_suppl.3021.Peer-Reviewed Original Research
2014
Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses
Roberts N, Zhang L, Janku F, Collins A, Bai R, Staedtke V, Rusk A, Tung D, Miller M, Roix J, Khanna K, Murthy R, Benjamin R, Helgason T, Szvalb A, Bird J, Roy-Chowdhuri S, Zhang H, Qiao Y, Karim B, McDaniel J, Elpiner A, Sahora A, Lachowicz J, Phillips B, Turner A, Klein M, Post G, Diaz L, Riggins G, Papadopoulos N, Kinzler K, Vogelstein B, Bettegowda C, Huso D, Varterasian M, Saha S, Zhou S. Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses. Science Translational Medicine 2014, 6: 249ra111. PMID: 25122639, PMCID: PMC4399712, DOI: 10.1126/scitranslmed.3008982.Peer-Reviewed Original ResearchConceptsC. novyi-NT sporesIntratumoral injectionHuman patientsCanine tumorsFurther clinical trialsOrthotopic brain tumor modelC. novyi-NTBrain tumor modelClostridium novyi-NT sporesSpontaneous solid tumorsCommon toxicitiesObjective responsePartial responseAdvanced leiomyosarcomaAntitumor responseClinical trialsHeterogeneous genetic backgroundHuman trialsSolid tumorsBacterial infectionsNeoplastic tissueTumor modelTumorsTherapeutic agentsPatientsIntegrins, Immunology
de Moll E, Dong J, Oliva M, Saenger Y. Integrins, Immunology. 2014, 1-9. DOI: 10.1007/978-1-4614-6613-0_131-1.Peer-Reviewed Original ResearchSuccessful human trialsAnti-integrin antibodiesIntegrin blockadeClinical trialsHuman trialsRole of integrinsPrincipal receptorTumor growthTumor proliferationTumor cellsMetastasisIntegrin expressionCell functionExtracellular matrix proteinsMultiple mechanismsTrialsAngiogenesisIntegrinsMatrix proteinsProliferationCell signalingMajor roleBlockade
2012
TCT-582 Eighteen Month Clinical and Imaging Results from the DESSOLVE I First-in-Human Trial of the MiStent® SES with Absorbable Polymer
Ormiston J, Stewart J, Webster M, Vrolix M, Whitbourn R, Donohoe D, Knape C, Lansky A, Bezerra H, Fitzgerald P, Kandzari D, Wijns W. TCT-582 Eighteen Month Clinical and Imaging Results from the DESSOLVE I First-in-Human Trial of the MiStent® SES with Absorbable Polymer. Journal Of The American College Of Cardiology 2012, 60: b169. DOI: 10.1016/j.jacc.2012.08.617.Peer-Reviewed Original ResearchFirst-in-Human Trial of a STAT3 Decoy Oligonucleotide in Head and Neck Tumors: Implications for Cancer Therapy
Sen M, Thomas SM, Kim S, Yeh JI, Ferris RL, Johnson JT, Duvvuri U, Lee J, Sahu N, Joyce S, Freilino ML, Shi H, Li C, Ly D, Rapireddy S, Etter JP, Li PK, Wang L, Chiosea S, Seethala RR, Gooding WE, Chen X, Kaminski N, Pandit K, Johnson DE, Grandis JR. First-in-Human Trial of a STAT3 Decoy Oligonucleotide in Head and Neck Tumors: Implications for Cancer Therapy. Cancer Discovery 2012, 2: 694-705. PMID: 22719020, PMCID: PMC3668699, DOI: 10.1158/2159-8290.cd-12-0191.Peer-Reviewed Original ResearchConceptsSTAT3 target genesTarget genesSTAT3 target gene expressionSTAT3-selective inhibitorsTarget gene expressionInhibited xenograft growthSelective STAT3 inhibitorSystemic administrationTranscription factor decoyTranscription factorsSTAT3 proteinBroader clinical developmentGene expressionPhase 0 trialsSTAT3 inhibitorHuman cancersSTAT3Expression levelsSTAT3 decoyCancer cellsCellular viabilityNeck cancerSaline controlsNeck tumorsHuman trials
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply